Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide
In this post hoc exploratory analysis, MASH resolution and fibrosis improvement were associated with body weight reduction, improved glycemic control, and normalization of liver fat. Weight reduction and metabolic improvements with tirzepatide treatment potentially contributed to disease modification in MASH.
Authors
- Melissa K. Thomas (ORCID: https://orcid.org/0000-0001-9848-2834)
- Rohit S. Loomba (ORCID: https://orcid.org/0000-0002-9116-2835)
- Yuanyuan Tang (ORCID: https://orcid.org/0000-0001-6873-9467)
- Cyrielle Caussy (ORCID: https://orcid.org/0000-0001-8089-2907)
- Elisabetta Bugianesi (ORCID: https://orcid.org/0000-0002-0502-4381)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
- Mark L. Hartman (ORCID: https://orcid.org/0000-0003-2396-7356)
- Kenneth Cusi (ORCID: https://orcid.org/0000-0002-8629-418X)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Eli Lilly (United States) (US)
- Virginia Commonwealth University (US)
- Medical City Dallas Hospital (US)
- University of Florida Health (US)
- University of Florida (US)
- University of California San Diego (US)
- 5T Torino (Italy) (IT)
- Hospices Civils de Lyon (FR)
- Hôpital Lyon Sud (FR)
- Centre de Recherche en Nutrition Humaine Rhône-Alpes (FR)
- Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition (FR)
- Torino e-district (IT)
- Department of Medical Sciences (BY)
- Velocity Clinical Research (United States) (US)
- University of Turin (IT)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-10-09
- DOI
- https://doi.org/10.2337/dc25-1306
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alnylam Pharmaceuticals
- Gilead Foundation
- Regeneron Pharmaceuticals
- Arrowhead Pharmaceuticals
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Novo Nordisk
- Genentech